secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001447362-24-000168
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M
--------------------------------------------------------------------------------

- Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.
- Total test reports 26,010 (+41% YoY); TissueCypher up 115%, IDgenetix up 81%, DecisionDx-SCC up 49%.
- Raises full-year 2024 revenue guidance to $320-330M from prior $275-300M.
- Cash, equivalents and marketable securities $279.8M at Sept 30, 2024.
- Q3 operating cash flow $23.3M vs $5.0M prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000168/0001447362-24-000168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000168/cstl-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001447362-24-000168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer